NorthSea Therapeutics B.V.
  • Home
  • About
  • Team
  • Presentations
  • Pipeline
  • News
  • Publications
  • Career
    • Job openings
  • Contact
Select Page

NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

25 Sep 2019 | News

Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases,...

NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO

4 Sep 2019 | News

Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of...

NorthSea Therapeutics

NorthSea Therapeutics is a clinical-stage biotech company developing first-in-class, oral, structurally engineered fatty acid therapeutics.

Contact

E: info@northseatherapeutics.com
T: +31 (0) 35 760 65 05

Address

Paasheuvelweg 25-C6
1105 BP Amsterdam
The Netherlands

© NorthSea Therapeutics B.V.